Converging evidence suggests that sleep disturbances can directly contribute to a transdiagnostic combination of behavior and neurocognitive difficulties characterizing most forms of psychopathology. However, it remains unclear how the growing comprehension of sleep neurophysiology should best inform sleep quality assessment in mental health patients. To address this fundamental question, we performed deep multimodal sleep and behavioral phenotyping in 37 individuals at high genetic risk for psychopathology due to 22q11.2 Deletion Syndrome (Mean age:19±8.17, M/F=22/15) and 34 Healthy Controls (Mean age:17.06±6.87, M/F=12/22). We implemented a multivariate analysis pipeline informed by the current neurobiological understanding of the behavioral consequences of sleep disruption. We detected multivariate patterns of disrupted sleep architecture consistently influenced by age and diagnosis across recordings and experimental settings. With high-density EEG polysomnography we detected atypical trajectories of Slow-Wave-Activity (SWA) reduction, influenced by age and sleep duration which, according to the Synaptic-Homeostasis-Hypothesis, could reflect combined alterations in neurodevelopmental and synaptic homeostasis mechanisms in 22q11DS. Blunted SWA reduction was linked with EEG markers of residual sleep pressure in morning-vs-evening EEG and with questionnaires estimating subjective somnolence in everyday life, potentially representing a clinically relevant signature of non-restorative sleep. Moreover, blunted SWA decline was linked to a transdiagnostic combination of behavioral difficulties, including negative psychotic symptoms, ADHD symptoms, and neurocognitive impairments in processing speed and inhibitory-control. These findings suggest that systematic screening and management of sleep disturbances could directly improve behavioral outcomes in 22q11DS. They highlight the potential of precision/multivariate phenotyping approaches for characterizing the role of sleep disturbances in developmental psychopathology.

The authors have declared no competing interest.

This study was funded by the Swiss National Science Foundation (SNSF) (Grant numbers: SE FNS 320030_179404 and FNS 320030_212476) and by the National Center of Competence in Research (NCCR) Synapsy-The Synaptic Bases of Mental Diseases (SNF, Grant number: 51NF40_185897). MauS (#162006) and CorrS (#209096) were supported by grants from the SNF.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of Commission Cantonale d'Ethique de la Recherche sur l'être humain gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors